Objective To describe the characteristics of cases with drug-associated rhabdomyolysis reported to the U.S. Food and Drug Administration (FDA). Methods A retrospective analysis of all drug-associated rhabdomyolysis cases reported to FDA between January 2004 and December 2009 was conducted. The analyses included the number of unique cases, age, gender, body weight and proportion of fatal outcome. Time to onset from beginning of the suspected drugs and frequently reported suspected drugs were also tabulated. Results There were 8,610 cases of drug-associated rhabdomyolysis in the database. Both case numbers and proportion of the fatal outcome appeared stable over the study period. Average age was 43.3 years old. The reported ratio of male to female was approximately 5 to 3. More than half of reported cases developed rhabdomyolysis within a month after beginning the suspected drug. Potential high risk groups for fatal outcome, such as age group younger than 10 years old and body weight group less than 50 kg were suggested. Suspected drugs for younger cases and their probable indication appear to be different from adult cases. There has been long standing controversial concern regarding an increased risk when a fibric acid derivative is added to an HMG-CoA reductase inhibitor. This study suggested that concomitant use of these two kinds of agents may be associated with a lower risk for fatal outcome, whereas renal dysfunction appeared to be associated with a higher risk for fatal outcome among the HMG-CoA reductase inhibitor-associated rhabdomyolysis cases. Conclusion The characteristics of cases of drug-associated rhabdomyolysis were described. Because of the various limitations of a spontaneous reporting-system database, the reported number should be interpreted with caution.
Introduction
Rhabdomyolysis is a potentially life-threatening syndrome, defined as necrosis of skeletal muscle and leakage of muscle-cell contents, including electrolytes, myoglobin, and other sarcoplasmic proteins. It is often caused by crush injuries to muscle, myocardial infarction, prolonged immobility, drug toxicities, hypothermia, and others (1, 2) Rhabdomyolysis is usually associated with symptoms such as muscle pain, weakness and brown urine, myoglobinuria, acute kidney injury, and markedly elevated creatine kinase levels. Acute kidney injury in myoglobinuria is caused by tubular injury resulting from excessive quantities of myoglobin. The incidence of rhabdomyolysis is difficult to establish owing to varying definitions and clinical scenarios. Moreover, since the rhabdomyolysis is a relatively rare condition, the rate of rhabdomyolysis in the general population is difficult to es-tablish with certainty, but it was estimated to be about 1-2 cases per 10,000 person-years for HMG-CoA reductase inhibitor-associated and HMG-CoA reductase inhibitorindependent rhabdomyolysis (3) . It is generally considered that the earlier diagnosis and treatment of rhabdomyolysis may be associated with a better outcome. Sufficient knowledge of rhabdomyolysis is essential for early detection of signals of rhabdomyolysis. The reported characteristics of patients are limited. Moreover, the reported characteristics vary widely according to the study population and severity of coexisting conditions. For example, mortality was reported to range from 3.4% to 32% among patients with rhabdomyolysis (4) .
In this study, I describe the characteristics of drugassociated rhabdomyolysis reported to the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). The FDA-AERS is a computerized information database designed to support the FDA's post-marketing safety surveillance program for all approved drug and therapeutic biologic products. Adverse drug reaction (ADR) reports have been entered into the AERS database since 1997 by drug and event. The drug manufacturers are required to report ADR associated with their drug products to FDA. FDA also receives ADR directly from health care professionals including physicians, pharmacists, and patients who were treated with the suspected drug. FDA allows the downloading the various data extracted from AERS database. The data currently contains more than 2.0 million ADR cases. Of the approximately 490,000 reports the FDA received and entered into the database in 2009. The FDA-ARES data do have some limitations. First of all, there is no certainty that the reported event was actually due to the product. Even though each provided individual case was reviewed by specialists, the causality assessment for each case is preliminary judgment and is only for regulatory purpose. Detailed causality assessment between reported ADR and the product will be done by reviewing aggregated reports later. Another limitation is that only a portion of all ADRs are reported to the FDA, which is called "underreporting". Since the exact number of population who are exposed to the drugs is not known, the incidence of the ADR associated with the drug cannot be calculated. The fraction of reports received by the FDA has been estimated to be 1% to 10%, but the absolute percentage is unknown (5) . In addition to the underreporting, since the report is highly dependent on spontaneous reports, there are many potential factors which may affect reporting. If errors occur randomly, the errors will reduce the potential signal and will be considered noise. Since the spontaneous report is made under less strict conditions than a clinical study, there may be chances for simple error. This kind of error usually results in noise. If the factor has an affect to mislead the results towards a specific direction, the factor may be called bias. For example, if the ADR is serious, physicians may want to report the ADR. This could make the cases in database shift to more serious events. In spite of underreporting, noise and potential bias in the AERS database, since the AERS is the biggest source of ADR, many approaches have been taken to use the AERS in quantitative epidemiologic studies and hypotheses creation in drug safety studies (6) (7) (8) (9) (10) . The data may allow me to describe the characteristics of drug-associated rhabdomyolysis based on analysis of the AERS.
Methods

DATA source
The AERS database was downloaded from FDA AERS web page (http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/). 
Case identification
Reports of rhabdomyolysis associated with any drug use were obtained from AERS database. Since reported ADR in AERS database are coded according to Medical Dictionary for Regulatory Activities (MedDRA) (http://www.meddramsso.com/public_about_meddra.asp MedDRA MSSO 3975 Virginia Mallory Drive Chantilly, VA 20151 USA), I identified rhabdomyolysis cases by preferred term (PT) coded as "rhabdomyolysis". There were 12,862 reports of rhabdomyolysis between 2004 and 2009. Duplicate reports are reports regarding the same case but the information in the reports is generally not identical. Usually a follow-up report with more detailed information or with longer term outcome is reported after the initial report. Since the AERS database has some duplicate reports, I removed the older one from duplicate reports by sorting by case identification number. After the removal of the duplicate report, there were 8,610 reports of rhabdomyolysis. The 8,610 reports were placed in further analysis. I used SMQ (Standardized MedDRA Queries; http://www.meddramsso.com/public_about_meddra.asp MSSO3975 Virginia Mallory Drive Chantilly, VA 20151 USA) code 20000003 to identify decline in renal function. The PT terms corresponding code 20000003 within the REAC table of FDA AERS were searched. This procedure was supposed to search for a relatively rapid decline in renal function that lead to any of following: the accumulation of water, crystalloid solutes, nitrogenous metabolites in the body, increase in serum creatinine and urea nitrogen levels (azotemia) greater than 0.5 and 10 mg per deciliter, respectively; oliguria; and changes in the rate of urine flow. Out of 2,523 HMG-CoA reductase inhibitor-associated rhabdomyolysis case, 996 cases (39.5%) were identified coexistence of renal dysfunction. The renal dysfunction search was intended to search for de novo onset in individuals whose baseline renal function was within normal limits and acute exacerbation of pre-existing chronic renal insufficiency.
Analysis
The identified reports were tabulated by reporting year, gender, age, body weight, and suspected drugs. Reporting year is calculated from reporting date (FDA_DT in the database) that is the date FDA received the report. Gender is calculated from gender code (GNDR_COD in the database). Age is calculated from age (AGE in the database) that is numeric value of patient's age at event. In this study, I converted all age in "years old" unit if the reported age is not in years old. Similarly, body weight is calculated from weight (WT in the database). If the unit was LBS (pounds), the numeric value was converted in kilograms by multiplying by 0.45359237. The suspected drugs are tabulated from DRUG data. It harbors not only suspected drugs but also concomitant drugs. In this study I tabulated only for suspected drugs. The duration between the beginning of medication and event onset was also tabulated. Since some information is missing, the number of reported cases is diverse between tabulations. DRUG data are first converted into substance name. In this study, terms used to search HMGCoA reductase inhibitors were as follows: simvastatin, atrovastatin, rosuvastatin, pravastatin, fluvastatin, losuvastatin, cerivastatin and pitavastatin. Similarly, terms for searching fibric acid derivatives included gmfibrozil, fenofibrate, bezafibrate and ciprofibrate.
Software
Microsoft Access 2003 (Microsoft Corporation, Redmond WA, USA) was used for data management and analyses. Analyses of 95% confidence interval of death proportion were performed using CDC EpiInfo software (the Centers for Disease Control and Prevention (CDC), Atlanta GA, USA).
Results and Discussion
As mentioned above, there were 8,610 cases reported as rhabdomyolysis. Among the 8,610 cases, 927 (10.8%) indicated fatal outcome. As a potential cause of the reported events, 16,435 suspected drugs were identified in the database.
Trend of reporting number and fatality of rhabdomyolysis cases are shown by reporting the year in Fig. 1 . The reporting in each year was between 1,280 and 1,569 cases (upper panel of Fig. 1 ). The proportion of fatal outcome in rhabdomyolysis was between 9.2% and 12.9% (lower panel of Fig. 1 ). There appears to be no meaningful tendency in both the reporting number and its fatal outcome proportion over the study period.
The reported case numbers for males and females were 4889 and 3036, respectively. The absolute case number in this observation study and odd ratio in a past case-control study should not be compared directly, but it has been previously reported that females were not significant but a higher odds ratio for HMG-CoA reductase inhibitor-associated rhabdomyolysis (11) . In the past case series report, only 21 HMG-CoA reductase inhibitor-associated rhabdomyolysis cases were analyzed. Thus, the power of demographics description in the past report may be limited. Despite the limitations of spontaneous ADR reporting, the difference of reporting in this database may reflect real facts to some extent. Since the drug-exposed population is not known, the incidence was not calculated. The difference of rhabdomyolysis reports among gender groups could be due to the difference of drug-exposed population number. And it also may possibly reflect the incidence of gender difference of rhabdomyolysis. The proportion of fatal outcome for males and females were 11.8% and 10.6%, respectively. The odds ratio for fatal outcome in females compared to males was 1.12 (95% CI: 0.97-1.30). The p-value calculated with Fisher's exact test was 0.121. Thus, the proportion of fatal outcome in both genders appeared to be similar.
The reporting number and fatality of rhabdomyolysis as categorized by age group are shown in Fig. 2 . For cases less than 80 years old, older age appears to be associated with a higher number of reporting. This trend appears to be similar if the reporting number is expressed in person-year in USA. The reporting rate was from 0.1 to 5.2 per million personyear as shown in upper panel of Fig. 2 . In the present study, the proportion of fatal outcome in cases aged between 80 and 89 did not appear to exceed the outcome of those aged between 10 and 79 (Fig. 2) . In contrast, for cases younger than10 years old, fatality appears to be higher if compared to those between 20 and 89. The odds ratio for fatal outcome in this age group compared to the other age group was 3.09 (95% CI; 1.94-4.91). The p-value calculated with Fisher's exact test was less than 0.0001. Thus it is suggested that the reporting number of cases younger than 10 years old may be low, but once the rhabdomyolysis developed the fatality may be relatively higher in this age group.
The reporting number and fatality of rhabdomyolysis in adults categorized by body weight group are shown in Fig. 3 . Since the younger age appears to be confounded with body weight, cases less than 20 years old were removed from this analysis. The reporting number was the highest in the weight group between 70 and 79 kg. The fatality appears to be higher in cases with a weight of less than 50 kg. Table 1 shows the 46 most frequently reported suspected drugs and the number of reports. Consistent with previous reports, lipid modifying agents, such as HMG-CoA reductase inhibitors were most frequently reported as a suspected cause of reported rhabdomyolysis (1, 12) . Since the HMGCoA reductase inhibitors are usually used in treatment of hyperlipidemia, which is well known to occur in adults, I also analyzed most frequently reported drugs in the younger age group. As shown in Table 2 , there were 123 suspected drugs reported in 100 rhabdomyolysis cases younger than 10 years old. No HMG-CoA reductase inhibitors were reported as a suspected drug. Instead, anesthetic agents, hemophilia therapeutic agents, antifungal agents, immunosuppressants and so on were listed. This indicates the underlying diseases of younger age group appeared to be quite different from those of adults. This may at least in part explain the higher fatal outcome proportion in this age gorup.
The mean daily dose for HMG-CoA reductase inhibitors, except for simvastatin, did not exceed the maximum daily dose in US prescribing information (Table 3) . Thus most HMG-CoA reductase inhibitor-treated cases might not be due to overdosing. Though, the mean daily dose for fluvastatin, pravastatin and simvastatin were higher than the maximum daily dose in the Japan prescribing information. Duration from beginning of suspected medication to the reported event onset (time to onset) is shown in Fig. 4 . Due to missing data, only a part (7,042 out of 16,435 suspected drugs) of 8,610 cases had a relevant date for beginning of medication and event onset date. Approximately 44.4% of reported cases of rhabdomyolysis occurred within a month after beginning of suspected drugs and up to 1,000 days from beginning of medication, approximately 90% of reported cases developed rhabdomyolysis.
Gemfibrozil was reported to increase the risk of rhabdomyolysis with HMG-CoA reductase inhibitors especially in patients with renal dysfunction (13) (14) (15) . According to a doctor's letter released in December 1999, cerivastatin and gemfibrozil (another cholesterol-lowering drug) should never be 79 (95%CI; 1.74-4.44) . p-value calculated with Fisher's exact test was less than 0.0001. *Similarly, the odds ratio for fatal outcome in the weight group 120kg or more was 1.80 (95%CI; 1.06-3.03) , with p-value 0.020.) used in combination due to the increased risk of a serious side effect, rhabdomyolysis. Then other HMG-CoA reductase inhibitors followed this safety communication. However, a recent open-label placebo controlled trial did not indicate such evidence for the increased risk for rhabdomyolysis when a fibric acid derivative is added to an HMG-CoA reductase inhibitor (16) . I analyzed regarding the concomitant use of HMG-CoA reductase inhibitors and fibric acid derivatives. In the previous report, one hundred and twentyfive cases (67.6%) out of 185 cerivastatin-associated rhabdomyolysis cases reported to AERS were prescribed concomitant gemfibrozil between September 1999 and July 2000 (17, 18) . On the other hand, only 220 cases (8.7%) out of 2,523 HMG-CoA reductase inhibitor-associated rhabdo- 
Table 2. Suspected Drugs in Rhabdomyolysis Cases Younger than 10 Years Old
This table shows suspected drugs reported more than once. There were 123 suspected drugs in 100 rhabdomyolysis cases younger than 10 years old. Drugs reported with fatal outcome are marked with (*). myolysis cases were prescribed concomitant fibric acid derivatives between January 2004 and December 2009. This reduced proportion of concomitant use may be due to the successful communication from regulatory health authorities and market authorization holders including the dear doctor's letter and prescribing information. Proportion of fatal outcome for HMG-CoA reductase inhibitor-associated rhabdomyolysis case with or without concomitant fibric acid derivatives were 5.5% (95% CI, 2.8-9.3) and 9.7% (95% CI, 8.5-11.0), respectively. Thus, the proportion for fatal outcome appeared to be lower in fibric acid derivatives cotreated subjects. The odds ratio for fatal outcome was 0.54 (95% CI; 0.28-1.01). The p-value calculated using Fisher's exact test was 0.0392.
Renal insufficiency is also reported to the risk of rhabdomyolysis with HMG-CoA reductase inhibitors (19) . As mentioned before, 2,523 cases out of 8,610 rhabdomyolysis case were treated with HMG-CoA reductase inhibitors. Out of 2,523 cases, 996 case (39.5%) were reported coexistence of renal dysfunction. The proportion for fatal outcome in with or without coexistence of renal dysfunction were 13.5% (95% CI; 11.4-15.8) and 6.6 % (95% CI; 5.4-8.0), respectively. The odds ratio for fatal outcome was 2.19 (95% CI; 1.66-2.91). P-value calculated with Fisher's exact test was less than 0.0001.) Thus, coexistence of renal dysfunction among the HMG-CoA reductase inhibitor-associated rhabdomyolysis cases appeared to be associated with a higher proportion of fatal outcome.
As mentioned above, there were 220 cases co-treated with both HMG-CoA reductase inhibitors and fibric acid derivatives. There were 114 and 106 cases among the 220 cotreated cases with and without renal dysfunction, respectively. The proportion for fatal outcome with or without coexistence of renal dysfunction was 10.5% (95% CI; 5.6-17.7) and 0.0% (95% CI; 0.0-3.4), respectively. The odds ratio for fatal outcome was 0.00 (95% CI; 0.00-0.43). P- values calculated using Fisher's exact test was 0.0006. Thus, the absence of renal dysfunction appears to be associated with the lower proportion of fatal outcome in the co-treated cases.
Conclusion
The characteristics of drug-associated rhabdomyolysis were evaluated by analyzing FDA AERS database. Potential high risk groups for fatal outcome, such as age group younger than 10 years old and body weight group of less than 50 kg are suggested. In addition to low body weight, a previously known risk factor, the underlying diseases in younger cases appeared to be different from those of adults. There has been a long-standing controversial concern regarding an increased risk for rhabdomyolysis when a fibric acid derivative is added to an HMG-CoA reductase inhibitor. The present data suggest that there was a much lower proportion of concomitant use of these substances compared to an earlier report. Moreover, concomitant use of these two kinds of agents appeared to be associated with a lower proportion of fatal outcome. Due to the following limitations, the suggested potential risk is only a signal of real risk of the fatal outcome. Further investigations are needed to determine whether the signal is real risk or not.
Limitations
As the nature of a spontaneous report, there are some limitations such as lack of a denominator. Since there is no information regarding the drug-exposed population, no incidence of ADR can be calculated. Other limitations are as follows; lack of research protocol, and duplicated case reports. Due to the lack of a research protocol, ADR reports are not systematically collected. This usually results in underreporting. There may be reporting bias and noise of information; it also may fail to collect possible confounding factors. Moreover, there is no certainty whether a reported event was actually the result of the suspected products or not.
